Tuberculosis during TNF-a inhibitor therapy, despite screening

Regina W. Hofland; Steven F.T. Thijsen; Marc A.M.T. Verhagen; Yolande Schenk; Ailko W.J. Bossink

doi:10.1136/thoraxjnl-2012-202974

Tuberculosis during TNF-a inhibitor therapy, despite screening

Regina W. Hofland^*, Steven F.T. Thijsen, Marc A.M.T. Verhagen, Yolande Schenk, Ailko W.J. Bossink

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

12 Citations (Scopus)

Abstract

As part of a prospective study on the safety of TNF-a inhibitor therapy after screening for and treatment of latent tuberculosis infection (LTBI), we report two patients who developed active tuberculosis (TB) infection during TNF-a inhibitor therapy, despite negative screening for LTBI. The clinical history is suggestive of a primary infection acquired during travelling to TB-endemic countries. In this lesson of the month we would like to highlight the risk of travelling to TBendemic areas in patients treated with TNF-a inhibitor therapy. Screening for latent tuberculosis infection is not enough to prevent tuberculosis in patients treated with TNF-a inhibitor therapy.

Original language	English
Pages (from-to)	1079-1080
Number of pages	2
Journal	Thorax
Volume	68
Issue number	11
DOIs	https://doi.org/10.1136/thoraxjnl-2012-202974
Publication status	Published - Nov 2013
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/thoraxjnl-2012-202974

Cite this

@article{dab1c989690d448f94b4d14e5f5c47ea,

title = "Tuberculosis during TNF-a inhibitor therapy, despite screening",

abstract = "As part of a prospective study on the safety of TNF-a inhibitor therapy after screening for and treatment of latent tuberculosis infection (LTBI), we report two patients who developed active tuberculosis (TB) infection during TNF-a inhibitor therapy, despite negative screening for LTBI. The clinical history is suggestive of a primary infection acquired during travelling to TB-endemic countries. In this lesson of the month we would like to highlight the risk of travelling to TBendemic areas in patients treated with TNF-a inhibitor therapy. Screening for latent tuberculosis infection is not enough to prevent tuberculosis in patients treated with TNF-a inhibitor therapy.",

author = "Hofland, {Regina W.} and Thijsen, {Steven F.T.} and Verhagen, {Marc A.M.T.} and Yolande Schenk and Bossink, {Ailko W.J.}",

year = "2013",

month = nov,

doi = "10.1136/thoraxjnl-2012-202974",

language = "English",

volume = "68",

pages = "1079--1080",

journal = "Thorax",

issn = "0040-6376",

publisher = "BMJ Publishing Group",

number = "11",

}

TY - JOUR

T1 - Tuberculosis during TNF-a inhibitor therapy, despite screening

AU - Hofland, Regina W.

AU - Thijsen, Steven F.T.

AU - Verhagen, Marc A.M.T.

AU - Schenk, Yolande

AU - Bossink, Ailko W.J.

PY - 2013/11

Y1 - 2013/11

N2 - As part of a prospective study on the safety of TNF-a inhibitor therapy after screening for and treatment of latent tuberculosis infection (LTBI), we report two patients who developed active tuberculosis (TB) infection during TNF-a inhibitor therapy, despite negative screening for LTBI. The clinical history is suggestive of a primary infection acquired during travelling to TB-endemic countries. In this lesson of the month we would like to highlight the risk of travelling to TBendemic areas in patients treated with TNF-a inhibitor therapy. Screening for latent tuberculosis infection is not enough to prevent tuberculosis in patients treated with TNF-a inhibitor therapy.

AB - As part of a prospective study on the safety of TNF-a inhibitor therapy after screening for and treatment of latent tuberculosis infection (LTBI), we report two patients who developed active tuberculosis (TB) infection during TNF-a inhibitor therapy, despite negative screening for LTBI. The clinical history is suggestive of a primary infection acquired during travelling to TB-endemic countries. In this lesson of the month we would like to highlight the risk of travelling to TBendemic areas in patients treated with TNF-a inhibitor therapy. Screening for latent tuberculosis infection is not enough to prevent tuberculosis in patients treated with TNF-a inhibitor therapy.

UR - http://www.scopus.com/inward/record.url?scp=84885853499&partnerID=8YFLogxK

U2 - 10.1136/thoraxjnl-2012-202974

DO - 10.1136/thoraxjnl-2012-202974

M3 - Article

C2 - 23598710

AN - SCOPUS:84885853499

SN - 0040-6376

VL - 68

SP - 1079

EP - 1080

JO - Thorax

JF - Thorax

IS - 11

ER -

Tuberculosis during TNF-a inhibitor therapy, despite screening

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this